StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.46−0.06 (-1.70%)

Close on Nov 17, 2026Market cap $224.08MP/E –Yield –

Immuneering gross margin

Gross margin is gross profit as a percentage of revenue.

Immuneering's gross margin for the twelve months ending Sep 30, 2023 was 100.0%. For fiscal 2022 it was 50.1%, against 44.6% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2022Dec 31, 202250.1%+5.5
FY2021Dec 31, 202144.6%−0.0
FY2020Dec 31, 202044.6%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2022Dec 31, 2022100.0%+108.8
Q3 FY2022Sep 30, 202249.6%−5.0
Q2 FY2022Jun 30, 202249.2%−2.5
Q1 FY2022Mar 31, 202250.5%+5.2
Q4 FY2021Dec 31, 2021-8.8%−37.6
Q3 FY2021Sep 30, 202154.6%+0.7
Q2 FY2021Jun 30, 202151.7%+1.0
Q1 FY2021Mar 31, 202145.3%–
Q4 FY2020Dec 31, 202028.8%–
Q3 FY2020Sep 30, 202053.9%–
Q2 FY2020Jun 30, 202050.7%–

More Immuneering figures

See a number that looks wrong?